Verzögert
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
0.53 AUD | +2.91% | +3.92% | -0.93% |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 01.05.12 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Thomas Jarrett
COO | Chief Operating Officer | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 01.10.12 |
Justin Ward
BRD | Director/Board Member | - | 01.01.16 |
Director/Board Member | - | 29.11.17 | |
Daniel Astudillo
SAM | Sales & Marketing | - | 01.04.18 |
Maggie Niewidok
SEC | Corporate Secretary | - | 01.09.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
John Prendergast
CHM | Chairman | 70 | 24.04.18 |
Alan Dunton
BRD | Director/Board Member | 70 | 14.07.20 |
Director/Board Member | - | 29.11.17 | |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 01.10.12 |
James Graham
CEO | Chief Executive Officer | - | 01.05.12 |
Justin Ward
BRD | Director/Board Member | - | 01.01.16 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 203 701 863 | 125 206 123 ( 61,47 %) | 0 | 61,47 % |
Unternehmenskontakt
Recce Pharmaceuticals Ltd.
Salesforce Tower 180 George Street
2000, Sydney
+61 2 9256 2505
http://www.recce.com.auSektor
Umsatz je Region
Verlauf des Gewinns je Aktie
Jahresgewinne - Abweichungsrate
% 1. Jan. | Kap. | |
---|---|---|
-0.93% | 69.3 Mio. | |
+27.97% | 676 Mrd. | |
+23.58% | 554 Mrd. | |
-7.02% | 349 Mrd. | |
+14.85% | 318 Mrd. | |
+6.25% | 291 Mrd. | |
+2.96% | 210 Mrd. | |
-0.41% | 204 Mrd. | |
-10.02% | 194 Mrd. | |
-11.81% | 144 Mrd. |
- Börse
- Aktien
- A2ADQM Aktie
- Unternehmen Recce Pharmaceuticals Ltd